Iloprost - AURLUMYN intravenous infusion

Use actual body weight. Begin IV infusion at 0.5 ng/kg/min; increase by 0.5 ng/kg/min every 30 minutes as tolerated, to at most 2 ng/kg/min. Infuse for six hours daily for up to eight consecutive days; the full label specifies subsequent-day titration.

At eGFR below 30 mL/min, retain the usual starting and titration approach; if 0.5 ng/kg/min is not tolerated, reduce to 0.25 ng/kg/min. Consider administration after hemodialysis or beginning dialysis at least one hour after the infusion finishes. Dialysis effects on exposure remain unassessed. Correct hypotension first and monitor vital signs.

This is the BTG label retrieved with a March 2026 prescribing-information revision, not the older Eicos labeling record whose marketing end date was listed in 2025.

The severe-renal instructions retain the usual starting infusion of 0.5 ng/kg/min and titration. At eGFR below 30 mL/min, if that starting rate is not tolerated, it may be reduced to 0.25 ng/kg/min. These are infusion rates, not intermittent doses.

The effect of hemodialysis on iloprost exposure has not been assessed. The source suggests dosing after dialysis or starting dialysis at least one hour after the infusion ends. Higher exposure observed on a dialysis-free day is not a measurement of dialysis removal. Correct hypotension before treatment and monitor vital signs.